Brief: Zydus Lifesciences and RK Pharma Enter Into Exclusive Licensing And Commercialization Agreement
Nov 26 (Reuters) - Zydus Lifesciences Ltd ZYDU.NS: ZYDUS LIFESCIENCES - ZYDUS, RK PHARMA ENTER INTO EXCLUSIVE LICENSING AND COMMERCIALIZATION AGREEMENT ZYDUS LIFESCIENCES - AGREEMENT FOR NOVEL STERILE INJECTABLE 505(B)(2) ONCOLOGY SUPPORTIVE CARE PRODUCT FOR US MARKET ZYDUS LIFESCIENCES - NOVEL STERILE INJECTABLE 505(B)(2) EXPECTED TO BE FILED IN 2026 Source text: [ID:] Further company coverage: ZYDU.NS ((Reuters.Briefs@thomsonreuters.com;))
Recent news on Zydus Lifesciences
See all newsIndia's Zydus Lifesciences posts lower profit as expenses outpace revenue growth
Brief: Zydus Lifesciences Q2 Consol Net Profit 9.26 Billion Rupees
Brief: Zydus Lifesciences Says Zylidac Bio And Prolific Machines Partner
Brief: Zydus Lifesciences Receives U.S. FDA Approval For Estradiol And Levonorgestrel Transdermal System
Brief: Zydus Lifesciences Says Zydus Sunshine Lifesciences Signs Agreement To Establish A Pharmaceutical Manufacturing Facility In Sri Lanka